Cathie's Ark Logo
Combined Holdings/CRSP/
CRISPR Therapeutics AG Logo

Combined Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

TherapeuticsGene TherapyCAR-T Cell TherapyCRSPR Gene Editing

Trades of CRSP Made In All Funds

Why do the number of shares of a company held in an ARK ETF go up or down even when no trades are reported?

Date
Direction
Shares
Fund Weight
Fund
December 29, 2022		BUY8.134k0.018%ARKG
December 28, 2022		BUY7.389k0.016%ARKG
December 27, 2022		BUY10.787k0.0231%ARKG
December 19, 2022		BUY17.738k0.0118%ARKK
December 19, 2022		BUY5.708k0.0124%ARKG

Key Statistics

⚖️Weighting🧢Market Cap
2.48%$3.49b
🏋️‍♀️Weight Rank Across All Funds🌏Country
15🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$70.01 - ARKG$62.32 - ARKK
8.91%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Website
www.crisprtx.com

Other ETFs That Hold CRSP

Ticker
NameWeight
ARKGARK Genomic Revolution ETF3.7%
GNOMGlobal X Genomics & Biotechnology ETF3.52%
ARKKARK Innovation ETF3.37%
XBISPDR® S&P Biotech ETF1.01%
IBBiShares Biotechnology ETF0.35%

Research Notes and Commentary for CRSP